Low-dose quetiapine use was associated with an increased risk of major adverse cardiovascular events compared to Z-drug hypnotics (aHR 1.13; 95% CI 1.02-1.24; p=0.014).
Cohort (n=515,133)
Yes
Does low-dose quetiapine increase the risk of major adverse cardiovascular events in adults without severe mental illness compared to Z-drug hypnotics?
Off-label use of low-dose quetiapine for sedative or hypnotic purposes is associated with an increased risk of major adverse cardiovascular events and cardiovascular death, and should be discouraged.
Hazard Ratio: 1.13 (95% CI 1.02–1.24)
p-value: p=0.014
At standard doses used for schizophrenia or bipolar disorder, quetiapine has been associated with weight gain and increased levels of triglycerides, to-tal cholesterol and low-density lipoprotein (LDL) cholesterol, which are risk factors for cardiovascular morbidity and mortality. However, this drug is also commonly used off-label at low doses for anxiolytic or hypnotic purposes, and its cardiovascular safety at these doses is unknown. We aimed to assess the risk of major adverse cardiovascular events with use of low-dose quetiapine compared to use of Z-drug hypnotics in a nationwide, active comparator-controlled cohort study. The cohort included new users of either drugs in Denmark from 2003 to 2017, aged 18-85 years, without history of ischemic stroke, myocardial infarction, cancer, and severe mental illness. The main outcome was the occurrence of major adverse cardiovascular events, defined as non-fatal myocardial infarction or ischemic stroke, or death from cardiovascular causes. Selective serotonin reuptake inhibitors (SSRIs) were used as an alternative comparator in sensitivity analyses. Altogether, we compared 60,566 low-dose quetiapine users with 454,567 Z-drug users, followed for 890,198 person-years in intent-to-treat analysis, and 330,334 person-years in as-treated analysis. In intention-to-treat analysis, low-dose quetiapine was associated with an increased risk of major adverse cardiovascular events (adjusted hazard ratio, aHR=1.13, 95% CI: 1.02-1.24, p=0.014) and cardiovascular death (aHR=1.26, 95% CI: 1.11-1.43, p<0.001). In as-treated analysis, continuous low-dose quetiapine use was associated with increased risk of major adverse cardiovascular events (aHR=1.52, 95% CI: 1.35-1.70, p<0.001), non-fatal ischemic stroke (aHR=1.37, 95% CI: 1.13-1.68, p=0.002) and cardiovascular death (aHR=1.90, 95% CI: 1.64-2.19, p<0.001). The risk of major adverse cardiovascular events was greater in women (aHR=1.28, p=0.02) and those aged ≥65 years at initiation (aHR=1.24, p<0.001). Compared to SSRIs, low-dose quetiapine use was associated with an increased risk of major adverse cardiovascular events (aHR=1.42, p<0.001), non-fatal ischemic stroke (aHR=1.27, p=0.0028) and cardiovascular death (aHR=1.72, p<0.001). So, we conclude that the use of low-dose quetiapine is associated with an increased risk of major adverse cardiovascular events, especially in women and the elderly. On the basis of these findings, we suggest that use of off-label low-dose quetiapine for sedative or hypnotic purposes should be discouraged.
Højlund et al. (Thu,) conducted a cohort in Off-label use for anxiolytic or hypnotic purposes (n=515,133). Low-dose quetiapine vs. Z-drug hypnotics was evaluated on Major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal ischemic stroke, or cardiovascular death) (aHR 1.13, 95% CI 1.02-1.24, p=0.014). Low-dose quetiapine use was associated with an increased risk of major adverse cardiovascular events compared to Z-drug hypnotics (aHR 1.13; 95% CI 1.02-1.24; p=0.014).